Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8890 · Enhancing CLIA Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 263a Certification of laboratories

+100 −54 of 5 shown
More for 42 U.S.C. § 263a
Read § 263aOnly this section
5 changes the bill asks for here, 4 carried out
  1. Carried out:

    by striking subsection (a) and inserting:(a) Scope of authority; definitions.— (1) Scope of authority.— Laboratory operations shall be regulated by the Secretary under this section and not under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et. seq.). (2) Definitions.— In this section: (A) Analytical validity.— The term analytical validity means, with respect to an examination or procedure performed by a laboratory, the ability of the examination or procedure to provide information that is accurate and reliable with respect to the identification, measurement, detection, or calculation of the target analyte in a specimen, within a reportable range. (B) Applicable standard.— The term applicable standard means— (i) for a laboratory developed test for clinical use, that the test has a reasonable assurance of analytical and clinical validity; and (ii) for a laboratory developed test for investigational use, that the test has a reasonable assurance of analytical validity. (C) Clinical use.— The term clinical use— (i) means that an examination or procedure is used for the purpose of providing information for the diagnosis, prognosis, identification, monitoring, screening, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings; and (ii) does not include— (I) investigational use; (II) research use; or (III) forensic use. (D) Clinical validity.— The term clinical validity means, with respect to an examination or procedure performed by a laboratory, the ability of the examination or procedure to provide information that is accurate and reliable for its stated clinical purpose. (E) Digital laboratory data.— The term digital laboratory data— (i) means digital data derived from a laboratory examination or procedure performed by a laboratory on materials taken or derived from the human body, including— (I) a digital image derived from a glass slide; (II) flow cytometry plots; (III) cytogenetic karyograms; (IV) chromatographic, mass spectrometric, clinical chemistry, immunological, hematological and microbiological data; (V) electropherograms; (VI) gel images; (VII) genetic expression, array and sequencing data; and (VIII) subsequent analyses of such data; and (ii) is patient-specific when it is accompanied by information that can be used to identify the individual from whose specimen the information was derived. (F) Investigational use.— The term investigational use means, with respect to a laboratory developed test, that the test is used in a clinical investigation, at least 1 purpose of which is to gather data to establish the clinical validity of the test. (G) Laboratory; clinical laboratory.— The term laboratory or clinical laboratory means a facility for the examination of materials taken or derived from the human body, including analysis of patient-specific digital laboratory data, for clinical use or investigational use. (H) Laboratory developed test.— The term laboratory developed test— (i) means an examination or procedure, including an examination or procedure that modifies an in vitro diagnostic device regulated under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), that is— (I) developed in a clinical laboratory certified under this section to perform tests of high-complexity; and (II) performed only within— (aa) the same clinical laboratory in which it was developed; or (bb) another clinical laboratory certified under this section to perform tests of high-complexity that is within— (AA) the same corporate organization and has common ownership by the same parent corporation as the developing laboratory; or (BB) a public health laboratory network coordinated or managed by the Centers for Disease Control and Prevention or other Federal public health agency, if the developing laboratory is a public health laboratory or a laboratory managed by the Centers for Disease Control and Prevention or other Federal public health agency; (ii) does not include a protocol for an examination or procedure that is commercially distributed for performance in laboratories not under common ownership by the same parent corporation as the laboratory that developed the protocol; (iii) is not a medical device subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), even if the laboratory developed test— (I) modifies the use of a device that is lawfully marketed under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); (II) requires preparation or modification within the laboratory of equipment, reagents, instruments, software, or other materials for use within the laboratory; (III) includes processes, materials, research, or intellectual property developed by third parties if the developing laboratory remains responsible for compliance with applicable requirements for laboratory developed tests under this section; or (IV) examines a specimen that was self-collected by an individual, regardless of the setting in which the specimen was collected; and (iv) is performed in a laboratory described in clause (i)(II) even if software used in the test is executed outside of the laboratory. (I) Laboratory operations.— The term laboratory operations— (i) means the conduct of examinations and other procedures on material taken or derived from the human body and associated activities, including analysis of patient-specific digital laboratory data, for a purpose described in subparagraph (E), including the development and performance of laboratory developed tests; and (ii) includes— (I) the preparation and transfer of equipment, reagents, instruments, software, or other materials between laboratories that are under common ownership by the same parent corporation; and (II) the distribution of specimen collection kits for use with laboratory developed tests if the components of such specimen collection kits are intended to be used consistent with the established intended uses for which they may otherwise be lawfully distributed. (J) Performance specifications.— The term performance specification means a value or range of values for a characteristic of an examination or procedure, such as accuracy, precision, analytical sensitivity, analytical specificity, reportable range, or other characteristic required for test performance. (K) Research use.— The term research use means, with respect to a laboratory developed test, that the test’s purpose is solely for analytical development or scientific research, and not for use in making clinical decisions for individual patients.;

  2. Not carried out:

    by adding at the end:(r) Laboratory developed tests.— (1) Reasonable assurance of analytical and clinical validity of laboratory developed tests.— (A) Standard.— Beginning 2 years after enactment of the Enhancing CLIA Act of 2026, no laboratory may perform a laboratory developed test unless the test meets the applicable standard. (B) Analytical validity.— For purposes of meeting the applicable standard under this section, a laboratory developed test has a reasonable assurance of analytical validity if— (i) the laboratory that develops the test establishes performance specifications that support the ability of the test to identify, measure, detect, calculate, or analyze 1 or more analytes, biomarkers, substances, or other targets intended to be identified, measured, detected, calculated, or analyzed by the test; and (ii) the laboratory that performs the test, if different than the laboratory that develops the test, verifies such performance specifications prior to use. (C) Clinical validity.— For purposes of meeting the applicable standard under this section, a laboratory developed test has a reasonable assurance of clinical validity if the laboratory that develops the test has documented evidence, which may include 1 or more of the following that supports the ability of the laboratory developed test to reliably and accurately achieve its stated purpose— (i) peer-reviewed literature; (ii) clinical guidelines; (iii) bench studies; (iv) case studies or histories; (v) consensus standards; (vi) reference standards; (vii) data registries; (viii) postmarket data; (ix) real world data; (x) 1 or more clinical validation studies; or (xi) other evidence deemed appropriate by the Secretary. (D) Supplemental affirmation that standard has been met.— (i) At any time, a laboratory may, but is not required to, obtain 1 or more supplemental affirmations that the laboratory developed test meets the applicable standard from a third party approved under subparagraph (E), pursuant to the process in subparagraph (F). Subject to clause (ii) of this subparagraph, such supplemental affirmation does not expire. (ii) If a third party approved under subparagraph (E) has its approval withdrawn by the Secretary, a supplemental affirmation that a laboratory developed test meets the applicable standard issued by that third party shall remain in effect for no longer than the later of— (I) 90 days after the date that a third party notifies a laboratory under subparagraph (E)(iv) that its approval has been withdrawn; or (II) if within 60 days of receiving the notification under subparagraph (E)(iv) the laboratory submits information to a different third party requesting a supplemental affirmation that the laboratory developed test meets the applicable standard, the date on which such approved third party determines whether the laboratory developed test meets the applicable standard under subparagraph (F)(i)(II). (E) Approved third parties.— Beginning 2 years after enactment of the Enhancing CLIA Act of 2026, the Secretary shall approve third parties to provide a supplemental affirmation that a laboratory developed test meets the applicable standard if— (i) the standards and procedures applied by the third party in determining whether the laboratory developed test meets the applicable standard are determined by the Secretary to be sufficiently risk-based, rigorous, and not overly burdensome; (ii) in the case that the third party determines under subparagraph (F)(ii)(III)(cc) that the data and information provided by the laboratory demonstrates that the laboratory developed test does not meet the applicable standard, the laboratory developed test is being offered with false or deceptive claims, or that it is probable that the test will cause serious adverse health consequences, the third party agrees to notify the Secretary within 10 days of such determination unless the laboratory stops offering, and notifies the third party that it no longer offers, the laboratory developed test; (iii) the third party agrees to notify the Secretary at least 30 days before it changes its standards and procedures for determining that a laboratory developed test meets the applicable standard; and (iv) if the third party has its approval withdrawn by the Secretary, the third party agrees to notify each laboratory that obtained a supplemental affirmation that the applicable standard was met for any laboratory developed test of the withdrawal within 10 days of the withdrawal. (F) Process for supplemental affirmation by approved third party.— (i) If a laboratory submits information to a third party approved by the Secretary under subparagraph (E) requesting a supplemental affirmation that a laboratory developed test meets the applicable standard, the approved third party shall within 60 calendar days of receipt of the submitted information— (I) review the submitted information, which may include communication with the laboratory; and (II) determine whether the laboratory developed test meets the applicable standard and communicate such determination with the laboratory as described in clause (ii). (ii) The approved third party shall provide written notice to the laboratory of the approved third party’s determination under clause (i)(II) as follows:(I) The approved third party shall notify the laboratory if the approved third party determines that the laboratory developed test— (aa) meets the applicable standard; or (bb) does not meet the applicable standard and subclauses (II) and (III) do not apply. (II) If the approved …

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: adding at the end: QCONTENT;
  3. Carried out:

    in subsection (e)(2)(A)(ii) by adding at the end except that such standards shall not require that laboratory developed tests offered by the laboratory have a supplemental affirmation from any approved third party that the applicable standard has been met,;

  4. Carried out:

    in subsection (i)(1)(C) by inserting or (r) after subsection (d); and

  5. Carried out:

    in subsection (o) by striking the period and inserting , except that the Secretary may not delegate to the Food and Drug Administration the responsibility or authority for determining whether any laboratory developed test meets the applicable standard under subsection (r)(4) of this section. Notwithstanding the prior sentence, the Food and Drug Administration may provide a supplemental affirmation that a laboratory developed test meets the applicable standard pursuant to subsection (r)(4)(F)..

§ 263a(a)–(c)

§ 263a. Certification of laboratories

(a) [struck: “Laboratory”][inserted: Scope] [struck: or][inserted: of] [struck: “clinical][inserted: authority;] [struck: laboratory” defined][inserted: definitions.—]

(1) [inserted: Scope of authority.—] [inserted: Laboratory operations shall be regulated by the Secretary under this section and not under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et. seq.).]

(2) [inserted: Definitions.—] [inserted: In this section:]

(A) [inserted: Analytical validity.—] [inserted: The term “analytical validity” means, with respect to an examination or procedure performed by a laboratory, the ability of the examination or procedure to provide information that is accurate and reliable with respect to the identification, measurement, detection, or calculation of the target analyte in a specimen, within a reportable range.]

(B) [inserted: Applicable standard.—] [inserted: The term “applicable standard” means—]

(i) [inserted: for a laboratory developed test for clinical use, that the test has a reasonable assurance of analytical and clinical validity; and]

(ii) [inserted: for a laboratory developed test for investigational use, that the test has a reasonable assurance of analytical validity.]

(C) [inserted: Clinical use.—] [inserted: The term “clinical use”—]

(i) [inserted: means that an examination or procedure is used for the purpose of providing information for the diagnosis, prognosis, identification, monitoring, screening, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings; and]

(ii) [inserted: does not include—]

(I) [inserted: investigational use;]

(II) [inserted: research use; or]

(III) [inserted: forensic use.]

(D) [inserted: Clinical validity.—] [inserted: The term “clinical validity” means, with respect to an examination or procedure performed by a laboratory, the ability of the examination or procedure to provide information that is accurate and reliable for its stated clinical purpose.]

(E) [inserted: Digital laboratory data.—] [inserted: The term “digital laboratory data”—]

(i) [inserted: means digital data derived from a laboratory examination or procedure performed by a laboratory on materials taken or derived from the human body, including—]

(I) [inserted: a digital image derived from a glass slide;]

(II) [inserted: flow cytometry plots;]

(III) [inserted: cytogenetic karyograms;]

(IV) [inserted: chromatographic, mass spectrometric, clinical chemistry, immunological, hematological and microbiological data;]

(V) [inserted: electropherograms;]

(VI) [inserted: gel images;]

(VII) [inserted: genetic expression, array and sequencing data; and]

(VIII) [inserted: subsequent analyses of such data; and]

(ii) [inserted: is patient-specific when it is accompanied by information that can be used to identify the individual from whose specimen the information was derived.]

(F) [inserted: Investigational use.—] [inserted: The term “investigational use” means, with respect to a laboratory developed test, that the test is used in a clinical investigation, at least 1 purpose of which is to gather data to establish the clinical validity of the test.]

(G) [inserted: Laboratory; clinical laboratory.—] [inserted: The term “laboratory” or “clinical laboratory” means a facility for the examination of materials taken or derived from the human body, including analysis of patient-specific digital laboratory data, for clinical use or investigational use.]

(H) [inserted: Laboratory developed test.—] [inserted: The term “laboratory developed test”—]

(i) [inserted: means an examination or procedure, including an examination or procedure that modifies an in vitro diagnostic device regulated under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), that is—]

(I) [inserted: developed in a clinical laboratory certified under this section to perform tests of high-complexity; and]

(II) [inserted: performed only within—]

(aa) [inserted: the same clinical laboratory in which it was developed; or]

(bb) [inserted: another clinical laboratory certified under this section to perform tests of high-complexity that is within—]

(AA) [inserted: the same corporate organization and has common ownership by the same parent corporation as the developing laboratory; or]

(BB) [inserted: a public health laboratory network coordinated or managed by the Centers for Disease Control and Prevention or other Federal public health agency, if the developing laboratory is a public health laboratory or a laboratory managed by the Centers for Disease Control and Prevention or other Federal public health agency;]

(ii) [inserted: does not include a protocol for an examination or procedure that is commercially distributed for performance in laboratories not under common ownership by the same parent corporation as the laboratory that developed the protocol;]

(iii) [inserted: is not a medical device subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), even if the laboratory developed test—]

(I) [inserted: modifies the use of a device that is lawfully marketed under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);]

(II) [inserted: requires preparation or modification within the laboratory of equipment, reagents, instruments, software, or other materials for use within the laboratory;]

(III) [inserted: includes processes, materials, research, or intellectual property developed by third parties if the developing laboratory remains responsible for compliance with applicable requirements for laboratory developed tests under this section; or]

(IV) [inserted: examines a specimen that was self-collected by an individual, regardless of the setting in which the specimen was collected; and]

(iv) [inserted: is performed in a laboratory described in clause (i)(II) even if software used in the test is executed outside of the laboratory.]

(I) [inserted: Laboratory operations.—] [inserted: The term “laboratory operations”—]

(i) [inserted: means the conduct of examinations and other procedures on material taken or derived from the human body and associated activities, including analysis of patient-specific digital laboratory data, for a purpose described in subparagraph (E), including the development and performance of laboratory developed tests; and]

(ii) [inserted: includes—]

(I) [inserted: the preparation and transfer of equipment, reagents, instruments, software, or other materials between laboratories that are under common ownership by the same parent corporation; and]

(II) [inserted: the distribution of specimen collection kits for use with laboratory developed tests if the components of such specimen collection kits are intended to be used consistent with the established intended uses for which they may otherwise be lawfully distributed.]

(J) [inserted: Performance specifications.—] [inserted: The term “performance specification” means a value or range of values for a characteristic of an examination or procedure, such as accuracy, precision, analytical sensitivity, analytical specificity, reportable range, or other characteristic required for test performance.]

(K) [inserted: Research use.—] [inserted: The term “research use” means, with respect to a laboratory developed test, that the test’s purpose is solely for analytical development or scientific research, and not for use in making clinical decisions for individual patients.]

[struck: As used in this section, the term “laboratory” or “clinical laboratory” means a facility for the biological, microbiological, serological, chemical, immuno-hematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.]

(b) Certificate requirement No person may solicit or accept materials derived from the human body for laboratory examination or other procedure unless there is in effect for the laboratory a certificate issued by the Secretary under this section applicable to the category of examinations or procedures which includes such examination or procedure.

(c) Issuance and renewal of certificates

§ 263a(e)(2)(A)In general(i)–(iv)

(c)(1)–(e)(2) unchanged ·

(i) using inspectors qualified to evaluate the methodologies used by the laboratories in performing laboratory examinations and other procedures, the accreditation body agrees to inspect a laboratory for purposes of accreditation with such frequency as determined by1 Secretary,

(ii) the standards applied by the body in determining whether or not to accredit a laboratory are equal to or more stringent than the standards issued by the Secretary under subsection (f),[inserted: except that such standards shall not require that laboratory developed tests offered by the laboratory have a supplemental affirmation from any approved third party that the applicable standard has been met,]

(iii) there is adequate provision for assuring that the standards of the accreditation body continue to be met by the laboratory,

(iv) in the case of any laboratory accredited by the body which has had its accreditation denied, suspended, withdrawn, or revoked or which has had any other action taken against it by the accrediting body, the accrediting body agrees to submit to the Secretary the name of such laboratory within 30 days of the action taken,

§ 263a(i)(1)In general(B)–(D)

(e)(2)(A)(v)–(i)(1)(A) unchanged ·

(B) has performed or represented the laboratory as entitled to perform a laboratory examination or other procedure which is not within a category of laboratory examinations or other procedures authorized in the certificate,

(C) has failed to comply with the requirements of subsection (d) or [inserted: (r) or ]the standards prescribed by the Secretary under subsection (f),

(D) has failed to comply with reasonable requests of the Secretary for—

(i) any information or materials, or

§ 263a(n)–(p)

(i)(1)(D)(ii)–(n)(5) unchanged ·

(6) a list of laboratories which have been excluded from participation under title XVIII or XIX of the Social Security Act [42 U.S.C. 1395 et seq., 1396 et seq.].

The information to be compiled under paragraphs (1) through (6) shall be information for the calendar year preceding the date the information is to be made available to the public and shall be accompanied by such explanatory information as may be appropriate to assist in the interpretation of the information compiled under such paragraphs.

(o) Delegation In carrying out this section, the Secretary may, pursuant to agreement, use the services or facilities of any Federal or State or local public agency or nonprofit private organization, and may pay therefor in advance or by way of reimbursement, and in such installments, as the Secretary may determine[inserted: , except that the Secretary may not delegate to the Food and Drug Administration the responsibility or authority for determining whether any laboratory developed test meets the applicable standard under subsection (r)(4) of this section].[inserted: Notwithstanding the prior sentence, the Food and Drug Administration may provide a supplemental affirmation that a laboratory developed test meets the applicable standard pursuant to subsection (r)(4)(F).]

(p) State laws

(1) Except as provided in paragraph (2), nothing in this section shall be construed as affecting the power of any State to enact and enforce laws relating to the matters covered by this section to the extent that such laws are not inconsistent with this section or with the regulations issued under this section.

Rest of § 263a unchanged ·

42 U.S.C. § 1395y Exclusions from coverage and medicare as secondary payer

Couldn't place the change
More for 42 U.S.C. § 1395y
Read § 1395yOnly this section

The bill's words for this section

  1. Not carried out:

    Section 1862(l)(1) of the Social Security Act (42 U.S.C. 1395y(l)(1)) is amended by adding at the end, For purposes of all existing and future national coverage determinations for a clinical laboratory diagnostic test, a supplemental affirmation from any approved third party that the applicable standard has been met under section 353 of the Public Health Services Act (42 U.S.C. 263a et seq.), as amended by the Enhancing CLIA Act of 2026 shall be considered equivalent to an approval or clearance under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.)..

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: adding at the end, QTEXT.

Step through the changes